Correlation of polypoid colorectal adenocarcinoma with pre-existing adenomatous polyps and KRAS mutation

Cancer Genetics

Volumn 204, Issue 5, 2011, Pages 245-251

  Chen, Hui ^a,b   Lefferts, Joel A ^a,b   Schwab, Mary C ^a,b   Suriawinata, Arief A ^a,b   Tsongalis, Gregory J ^a,b  

^a NORRIS COTTON CANCER CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Adenomatous polyp with villous architecture; Colorectal adenocarcinoma; KRAS; Villous adenoma

Indexed keywords

CETUXIMAB; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; COLON POLYPOSIS; COLON ULCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TISSUE SECTION; VILLOUS ADENOMA; ADENOCARCINOMA; ADENOMATOUS POLYP; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ADENOMATOUS POLYPS; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 80051597182     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.04.002     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
3. Lenz H.J., Van Cutsem E., Khambata-Ford S., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006, 24:4914-4921.
4. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
5. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007, 67:2643-2648.
6. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
7. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261.
8. Tabernero J., Cervantes A., Rivera F., et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010, 28:1181-1189.
9. De Roock W., Jonker D.J., Di Nicolantonio F., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304:1812-1820.
10. Yuen S.T., Davies H., Chan T.L., et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002, 62:6451-6455.
11. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12:5268-5272.
12. Bar-Sagi D., Hall Ras and Rho GTPases: a family reunion. Cell 2000, 103:227-238.
13. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
14. Cerutti P., Hussain P., Pourzand C., et al. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res 1994, 54(7 Suppl):1934s-1938s.
15. Lau K.S., Haigis K.M. Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer. Mol Cells 2009, 28:315-320.
16. Maltzman T., Knoll K., Martinez M.E., et al. Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology 2001, 121:302-309.
17. Einspahr J.G., Martinez M.E., Jiang R., et al. Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics. Cancer Epidemiol Biomarkers Prev 2006, 15:1443-1450.
18. Barry E.L., Baron J.A., Grau M.V., et al. K-ras mutations in incident sporadic colorectal adenomas. Cancer 2006, 106:1036-1040.
19. Jass J.R., Baker K., Zlobec I., et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a " fusion" pathway to colorectal cancer. Histopathology 2006, 49:121-131.
20. Risio M., Malacarne D., Giaretti W. KRAS transitions and villous growth in colorectal adenomas. Cell Oncol 2005, 27:363-366.
21. Lievre A., Bachet J.-B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
22. Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50:113-130.
23. Hornick J.L., Odze R.D. Polyps of the large interstine. Surgical pathology of the GI tract, liver, biliary tract, and pancreas 2009, 481-533. Saunders Elsevier, Philadelphia, PA. 2nd ed. R.D. Odze, J.R. Goldblum (Eds.).
24. Redston M. Epithelial neoplasms of the large intestine. Surgical pathology of the GI tract, liver, biliary tract, and pancreas 2009, 597-637. Saunders Elsevier, Philadelphia, PA. 2nd ed. R.D. Odze, J.R. Goldblum (Eds.).
25. Laghi L., Bianchi P., Malesci A. Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 2008, 27:6313-6321.
26. Chan T.L., Zhao W., Leung S.Y., et al. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 2003, 63:4878-4881.
27. Higuchi T., Jass J.R. My approach to serrated polyps of the colorectum. J Clin Pathol 2004, 57:682-686.
28. Kakar S., Deng G., Cun L., et al. CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size, site, and villous component. Hum Pathol 2008, 39:30-36.